Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 1;11(4):932-939.
doi: 10.7150/jca.33105. eCollection 2020.

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Junshang Ge  1   2   3 , Jie Wang  2 , Hui Wang  1 , Xianjie Jiang  2 , Qianjin Liao  1 , Qian Gong  1 , Yongzhen Mo  2 , Xiaoling Li  1   2   3 , Guiyuan Li  1   2   3 , Wei Xiong  1   2   3 , Jin Zhao  1   2 , Zhaoyang Zeng  1   2   3
Affiliations

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Junshang Ge et al. J Cancer. .

Abstract

Objective: To investigate the correlation between the BRAF V600E gene mutation and clinicopathological features and thyroid function after iodine-131 treatment in patients with papillary thyroid cancer (PTC). Methods: A total of 128 PTC patients who underwent iodine-131 treatment after a total thyroidectomy from February 2015 to November 2016 at Hunan Cancer Hospital, China, were recruited. There were 25 males and 103 females. The age range was 11 to 73 years old. The BRAF V600E mutation in tumor tissues was detected by amplification-restriction mutation system polymerase chain reaction (ARMS-PCR), and the serum levels of Tg, TSH, Tg-Ab, and Tpo-Ab were measured by chemiluminescence after iodine-131 treatment. The BRAF V600E mutation was shown to be associated with clinicopathological characteristics and thyroid function indicators after iodine-131 treatment. Results: BRAF V600E mutation was detected in 75 of the 128 patients (58.6%) and was observed more frequently in cases with elevated Tg levels (Tg>1.00) at 3, 6, 12, and 18 months after treatment compared with patients without any BRAF mutations (P<0.05). Patients with BRAF V600E mutation had significant lower level of Tg-Ab at 3 and 12 months after treatment with iodine-131 than patients without BRAF V600E mutation (P<0.05). Among the 75 BRAF V600E patients, no significant association was found between the levels of TSH and Tpo-Ab after iodine-131 treatment (P>0.05). The BRAF V600E mutation was closely associated with the high-risk and age of the patient (≥45 years old) (P<0.05), but there was no significant correlation with gender, clinical stage, and distant metastasis. Conclusion: The BRAF V600E mutation is closely related to serum Tg elevation after treatment with iodine-131 in papillary thyroid cancer. These findings suggest that this BRAF mutation may be a predictor of the efficacy of iodine-131 treatment for papillary thyroid cancer.

Keywords: BRAF V600E; I -131 treatment; Thyroid function; papillary thyroid carcinoma.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Tg levels in the 3rd, 6th, 12th, 18th, and 24th months after thyroid cancer treatment with iodine-131 in 128 patients from Hunan Cancer Hospital (error bar: mean with SEM).
Figure 2
Figure 2
The rate of elevated Tg levels in the 3rd, 6th, 12th, 18th and 24th months after thyroid cancer treatment with iodine-131.
Figure 3
Figure 3
Tg-Ab levels in the 3rd (A), 6th (B), 12th (C)and 18th (D) month after thyroid cancer treatment with iodine-131in 128 patients from Hunan Cancer Hospital (error bar: mean with SEM).
See this image and copyright information in PMC

References

    1. Mao Y, Xing M. Recent incidences and differential trends of thyroid cancer in the USA. Endocr Relat Cancer. 2016;23:313–22. - PMC - PubMed
    1. Doubleday A, Sippel RS. Surgical options for thyroid cancer and post-surgical management. Expert Rev Endocrinol Metab. 2018;13:137–48. - PubMed
    1. American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C, Cooper DS, Doherty GM, Haugen BR, Kloos RT, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214. - PubMed
    1. Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C. et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17:45. - PMC - PubMed
    1. Long GV, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V. et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017;377:1813–23. - PubMed